EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

EGFR- and Integrin αVβ3-Targeting Peptides as Potential Radiometal-Labeled Radiopharmaceuticals for Cancer Theranostics

Cibele Rodrigues Toledo iD, Ahmed A Tantawy, Leonardo Lima Fuscaldi iD, Luciana Malavolta iD, Carolina de Aguiar Ferreira iD

International Journal of Molecular Sciences · 05.08.2024 · 25 (15) · 8553

DOI: 10.3390/ijms25158553 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.08.2024. Verfasst von Cibele Rodrigues Toledo und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Institute for Quantitative Health Science & Engineering, Michigan State University, East Lansing, MI 48824, USA. Hauptthemen laut MEDLINE: Integrin alphaVbeta3, ErbB Receptors, Radiopharmaceuticals, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Theranostics Innovation Center (CancerThera) / Centros de Pesquisa, Inovação e Difusão (CEPID) / Fundação de Amparo à Pesquisa do Estado de São Paulo (F…, Cancer Theranostics Innovation Center (CancerThera).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The burgeoning field of cancer theranostics has witnessed advancements through the development of targeted molecular agents, particularly peptides. These agents exploit the overexpression or mutations of specific receptors, such as the Epidermal Growth Factor receptor (EGFR) and αVβ3 integrin, which are pivotal in tumor growth, angiogenesis, and metastasis. Despite the extensive research into and promising outcomes associated with antibody-based therapies, peptides offer a compelling alternative due to their smaller size, ease of modification, and rapid bioavailability, factors which potentially enhance tumor penetration and reduce systemic toxicity. However, the application of peptides in clinical settings has challenges. Their lower binding affinity and rapid clearance from the bloodstream compared to antibodies often limit their therapeutic efficacy and diagnostic accuracy. This overview sets the stage for a comprehensive review of the current research landscape as it relates to EGFR- and integrin αVβ3-targeting peptides. We aim to delve into their synthesis, radiolabeling techniques, and preclinical and clinical evaluations, highlighting their potential and limitations in cancer theranostics. This review not only synthesizes the extant literature to outline the advancements in peptide-based agents targeting EGFR and integrin αVβ3 but also identifies critical gaps that could inform future research directions. By addressing these gaps, we contribute to the broader discourse on enhancing the diagnostic precision and therapeutic outcomes of cancer treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Integrin alphaVbeta3ErbB ReceptorsRadiopharmaceuticalsNeoplasmsPeptidesHumansAnimalsPrecision MedicineTheranostic Nanomedicine

Stichwörter der Autor:innen

EGFRcancerintegrin αVβ3theranostics

Substanzen

Integrin alphaVbeta3ErbB ReceptorsRadiopharmaceuticalsPeptidesEGFR protein, human

Autor:innen und Institutionen

  • The Institute for Quantitative Health Science & Engineering, Michigan State University, East Lansing, MI 48824, USA.
  • Comparative Medicine and Integrative Biology, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, USA.
  • Department of Physiological Sciences, Santa Casa de Sao Paulo School of Medical Sciences, São Paulo 01221-020, Brazil.
  • Department of Radiology, Michigan State University, East Lansing, MI 48824, USA.
  • Department of Pharmacology & Toxicology, Michigan State University, East Lansing, MI 48824, USA.
  • Department of Biomedical Engineering, Michigan State University, East Lansing, MI 48824, USA.

ORCID-Profile: Cibele Rodrigues Toledo, Leonardo Lima Fuscaldi, Luciana Malavolta, Carolina de Aguiar Ferreira

Förderung

  • Cancer Theranostics Innovation Center (CancerThera) / Centros de Pesquisa, Inovação e Difusão (CEPID) / Fundação de Amparo à Pesquisa do Estado de São Paulo (F…
  • Cancer Theranostics Innovation Center (CancerThera)

Zitieren

APA

Rodrigues Toledo, C., Tantawy, A. A., Lima Fuscaldi, L., Malavolta, L., & de Aguiar Ferreira, C. (2024). EGFR- and Integrin αVβ3-Targeting Peptides as Potential Radiometal-Labeled Radiopharmaceuticals for Cancer Theranostics. International Journal of Molecular Sciences, 25(15), 8553. https://doi.org/10.3390/ijms25158553

Vancouver

Rodrigues Toledo C, Tantawy AA, Lima Fuscaldi L, Malavolta L, de Aguiar Ferreira C. EGFR- and Integrin αVβ3-Targeting Peptides as Potential Radiometal-Labeled Radiopharmaceuticals for Cancer Theranostics. International Journal of Molecular Sciences. 2024;25(15):8553. doi:10.3390/ijms25158553

BibTeX
@article{RodriguesToledo2024,
  author = {Rodrigues Toledo, Cibele and Tantawy, Ahmed A and Lima Fuscaldi, Leonardo and Malavolta, Luciana and de Aguiar Ferreira, Carolina},
  title = {EGFR- and Integrin αVβ3-Targeting Peptides as Potential Radiometal-Labeled Radiopharmaceuticals for Cancer Theranostics},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {15},
  pages = {8553},
  doi = {10.3390/ijms25158553}
}
Kostenlos starten →